

William E Whitehead

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/759742/publications.pdf>

Version: 2024-02-01

141
papers

21,036
citations

15466

65
h-index

11288

136
g-index

142
all docs

142
docs citations

142
times ranked

9127
citing authors

#	ARTICLE	IF	CITATIONS
1	U. S. Householder survey of functional gastrointestinal disorders. <i>Digestive Diseases and Sciences</i> , 1993, 38, 1569-1580.	1.1	1,995
2	Prevalence of Symptomatic Pelvic Floor Disorders in US Women. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1311.	3.8	1,397
3	AGA technical review on irritable bowel syndrome. <i>Gastroenterology</i> , 2002, 123, 2108-2131.	0.6	1,247
4	Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?. <i>Gastroenterology</i> , 2002, 122, 1140-1156.	0.6	944
5	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , 2021, 160, 99-114.e3.	0.6	913
6	Tolerance for Rectosigmoid Distention in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 1990, 98, 1187-1192.	0.6	579
7	Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders 1 1This study was registered with ClinicalTrials.gov (trial registry no.) Tj ETQq1 1 0.784314 rgBT /@68rlock 10	0.6	521
8	Irritable bowel syndrome: A technical review for practice guideline development. <i>Gastroenterology</i> , 1997, 112, 2120-2137.	0.6	521
9	Fecal Incontinence in US Adults: Epidemiology and Risk Factors. <i>Gastroenterology</i> , 2009, 137, 512-517.e2.	0.6	521
10	Symptoms of Psychologic Distress Associated With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 1988, 95, 709-714.	0.6	469
11	Irritable bowel syndrome. <i>Digestive Diseases and Sciences</i> , 1980, 25, 404-413.	1.1	455
12	AGA technical review on anorectal testing techniques. <i>Gastroenterology</i> , 1999, 116, 735-760.	0.6	419
13	Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. <i>Gastroenterology</i> , 2016, 150, 1481-1491.	0.6	400
14	Biofeedback Is Superior to Laxatives for Normal Transit Constipation Due to Pelvic Floor Dyssynergia. <i>Gastroenterology</i> , 2006, 130, 657-664.	0.6	398
15	The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. <i>Gut</i> , 2017, 66, 1075-1082.	6.1	368
16	Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. The Working Team of Glaxo-Wellcome Research, UK. <i>Digestive Diseases and Sciences</i> , 1997, 42, 223-241.	1.1	347
17	Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. <i>American Journal of Gastroenterology</i> , 2000, 95, 999-1007.	0.2	340
18	Biofeedback Benefits Only Patients With Outlet Dysfunction, Not Patients With Isolated Slow Transit Constipation. <i>Gastroenterology</i> , 2005, 129, 86-97.	0.6	328

#	ARTICLE	IF	CITATIONS
19	Is rectal pain sensitivity a biological marker for irritable bowel syndrome: Psychological influences on pain perception. <i>Gastroenterology</i> , 1998, 115, 1263-1271.	0.6	288
20	Design of Treatment Trials for Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2006, 130, 1538-1551.	0.6	269
21	Randomized, Controlled Trial Shows Biofeedback to be Superior to Alternative Treatments for Patients with Pelvic Floor Dyssynergia-Type Constipation. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 428-441.	0.7	266
22	ACG Clinical Guideline: Management of Benign Anorectal Disorders. <i>American Journal of Gastroenterology</i> , 2014, 109, 1141-1157.	0.2	265
23	Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. <i>Gastroenterology</i> , 2020, 158, 1262-1273.e3.	0.6	249
24	Epidemiology, Pathophysiology, and Classification of Fecal Incontinence: State of the Science Summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop. <i>American Journal of Gastroenterology</i> , 2015, 110, 127-136.	0.2	219
25	Mindfulness Training Reduces the Severity of Irritable Bowel Syndrome in Women: Results of a Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2011, 106, 1678-1688.	0.2	218
26	Treatment options for fecal incontinence. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 131-142.	0.7	207
27	Randomized Controlled Trial Shows Biofeedback to be Superior to Pelvic Floor Exercises for Fecal Incontinence. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1730-1737.	0.7	206
28	Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 252-262.	3.7	199
29	Anorectal functional testing: review of collective experience1. <i>American Journal of Gastroenterology</i> , 2002, 97, 232-240.	0.2	197
30	Design of Treatment Trials for Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2016, 150, 1469-1480.e1.	0.6	195
31	The international anorectal physiology working group (IAPWG) recommendations: Standardized testing protocol and the London classification for disorders of anorectal function. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13679.	1.6	184
32	Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. <i>Current Gastroenterology Reports</i> , 2017, 19, 15.	1.1	181
33	Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 237-248.	1.9	177
34	Comorbidity in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2007, 102, 2767-2776.	0.2	176
35	Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. <i>Digestive Diseases and Sciences</i> , 2002, 47, 2605-2614.	1.1	172
36	Inability of the Rome III Criteria to Distinguish Functional Constipation From Constipation-Subtype Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2010, 105, 2228-2234.	0.2	166

#	ARTICLE	IF	CITATIONS
37	Functional disorders of the anus and rectum. <i>Gut</i> , 1999, 45, ii55-ii59.	6.1	158
38	Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. <i>Gut</i> , 2007, 56, 1202-1209.	6.1	154
39	Association of Low Dietary Intake of Fiber and Liquids With Constipation: Evidence From the National Health and Nutrition Examination Survey. <i>American Journal of Gastroenterology</i> , 2013, 108, 796-803.	0.2	148
40	Biofeedback treatment of fecal incontinence. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 728-736.	0.7	147
41	Irritable bowel syndrome defined by factor analysis gender and race comparisons. <i>Digestive Diseases and Sciences</i> , 1995, 40, 2647-2655.	1.1	143
42	The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries. <i>American Journal of Gastroenterology</i> , 2018, 113, 86-96.	0.2	138
43	Contributions of Pain Sensitivity and Colonic Motility to IBS Symptom Severity and Predominant Bowel Habits. <i>American Journal of Gastroenterology</i> , 2008, 103, 2550-2561.	0.2	134
44	Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. <i>Gastroenterology</i> , 1990, 98, 336-340.	0.6	132
45	Validation of the Balloon Evacuation Test: Reproducibility and Agreement With Findings From Anorectal Manometry and Electromyography. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2049-2054.	2.4	131
46	Biofeedback Treatment of Constipation. <i>Diseases of the Colon and Rectum</i> , 2003, 46, 1208-1217.	0.7	130
47	Sensory retraining is key to biofeedback therapy for formed stool fecal incontinence. <i>American Journal of Gastroenterology</i> , 2002, 97, 109-117.	0.2	124
48	Psychological Treatments in Functional Gastrointestinal Disorders: A Primer for the Gastroenterologist. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 208-216.	2.4	118
49	Complementary and alternative medicine use and cost in functional bowel disorders: A six month prospective study in a large HMO. <i>BMC Complementary and Alternative Medicine</i> , 2008, 8, 46.	3.7	111
50	Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 137-146.	1.9	101
51	Fecal incontinence in primary care: prevalence, diagnosis, and health care utilization. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 493.e1-493.e6.	0.7	97
52	Pain from rectal distension in women with irritable bowel syndrome: relationship to sexual abuse. <i>Digestive Diseases and Sciences</i> , 1997, 42, 796-804.	1.1	96
53	Mechanisms of Constipation in Older Persons and Effects of Fiber Compared with Placebo. <i>Journal of the American Geriatrics Society</i> , 1995, 43, 666-669.	1.3	91
54	Risk Factors for Urinary, Fecal, or Dual Incontinence in the Nurses' Health Study. <i>Obstetrics and Gynecology</i> , 2013, 122, 539-545.	1.2	90

#	ARTICLE	IF	CITATIONS
55	How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. <i>American Journal of Gastroenterology</i> , 2018, 113, 1017-1025.	0.2	90
56	Validation of Symptom-Based Diagnostic Criteria for Irritable Bowel Syndrome: A Critical Review. <i>American Journal of Gastroenterology</i> , 2010, 105, 814-820.	0.2	89
57	Risk Factors for Fecal Incontinence in Older Women. <i>American Journal of Gastroenterology</i> , 2013, 108, 113-119.	0.2	87
58	Biofeedback Treatment for Functional Anorectal Disorders: A Comprehensive Efficacy Review. <i>Applied Psychophysiology Biofeedback</i> , 2004, 29, 153-174.	1.0	86
59	The usual medical care for irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1305-1315.	1.9	74
60	Treatment of Fecal Incontinence: State of the Science Summary for the National Institute of Diabetes and Digestive and Kidney Diseases Workshop. <i>American Journal of Gastroenterology</i> , 2015, 110, 138-146.	0.2	74
61	The impact of fecal and urinary incontinence on quality of life 6 months after childbirth. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 636.e1-636.e6.	0.7	73
62	IBS Patients Show Frequent Fluctuations Between Loose/Watery and Hard/Lumpy Stools: Implications for Treatment. <i>American Journal of Gastroenterology</i> , 2012, 107, 286-295.	0.2	72
63	Reports of "Satisfactory Relief" by IBS Patients Receiving Usual Medical Care Are Confounded by Baseline Symptom Severity and Do Not Accurately Reflect Symptom Improvement. <i>American Journal of Gastroenterology</i> , 2006, 101, 1057-1065.	0.2	70
64	Loperamide Versus Psyllium Fiber for Treatment of Fecal Incontinence. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 983-993.	0.7	67
65	Psychometric Evaluation of Patient-Reported Outcomes in Irritable Bowel Syndrome Randomized Controlled Trials: A Rome Foundation Report. <i>Gastroenterology</i> , 2009, 137, 1944-1953.e3.	0.6	66
66	ACG Clinical Guidelines: Management of Benign Anorectal Disorders. <i>American Journal of Gastroenterology</i> , 2021, 116, 1987-2008.	0.2	58
67	Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). <i>BioPsychoSocial Medicine</i> , 2007, 1, 6.	0.9	57
68	Irritable Bowel Syndrome Subtypes Defined by Rome II and Rome III Criteria are Similar. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 214-220.	1.1	57
69	Habit Training as Treatment of Encopresis Secondary to Chronic Constipation. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1985, 4, 397-401.	0.9	54
70	Management of the multiple symptoms of irritable bowel syndrome. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 112-122.	3.7	54
71	Hypnosis Home Treatment for Irritable Bowel Syndrome:A Pilot Study. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2006, 54, 85-99.	1.1	53
72	Diagnosis and Treatment of Pelvic Floor Disorders: What's New and What to Do. <i>Gastroenterology</i> , 2010, 138, 1231-1235.e4.	0.6	53

#	ARTICLE	IF	CITATIONS
73	Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e945-e956.	2.4	52
74	Brief telephone-delivered cognitive behavioral therapy targeted to parents of children with functional abdominal pain: a randomized controlled trial. <i>Pain</i> , 2017, 158, 618-628.	2.0	49
75	Diagnosing and Managing Fecal Incontinence: If You Don't Ask, They Won't Tell. <i>Gastroenterology</i> , 2005, 129, 6.	0.6	48
76	The role of biofeedback in the treatment of gastrointestinal disorders. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 371-382.	1.7	48
77	Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 281-283.	1.4	46
78	Controlling faecal incontinence in women by performing anal exercises with biofeedback or loperamide: a randomised clinical trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 698-710.	3.7	44
79	Social learning contributions to the etiology and treatment of functional abdominal pain and inflammatory bowel disease in children and adults. <i>World Journal of Gastroenterology</i> , 2007, 13, 2397.	1.4	44
80	Control groups appropriate for behavioral interventions. <i>Gastroenterology</i> , 2004, 126, S159-S163.	0.6	43
81	Hypnosis for Irritable Bowel Syndrome: The Empirical Evidence of Therapeutic Effects. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2006, 54, 7-20.	1.1	43
82	Survey of Geriatricians on the Effect of Fecal Incontinence on Nursing Home Referral. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 1058-1062.	1.3	42
83	Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2011, 23, 944.	1.6	40
84	Mindfulness for irritable bowel syndrome: protocol development for a controlled clinical trial. <i>BMC Complementary and Alternative Medicine</i> , 2009, 9, 24.	3.7	39
85	Validity and Reliability of the Japanese Version of the Rome III Diagnostic Questionnaire for Irritable Bowel Syndrome and Functional Dyspepsia. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 537-544.	0.8	39
86	Fecal Incontinence Diagnosed by the Rome IV Criteria in the United States, Canada, and the United Kingdom. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 385-391.	2.4	37
87	Is functional dyspepsia just a subset of the irritable bowel syndrome?. <i>Bailliere's Clinical Gastroenterology</i> , 1998, 12, 443-461.	0.9	35
88	Elevated Vasoactive Intestinal Peptide Concentrations in Patients with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1236-1243.	1.1	35
89	Episodic Nature of Symptoms in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2014, 109, 1450-1460.	0.2	34
90	Rome III survey of irritable bowel syndrome among ethnic Malays. <i>World Journal of Gastroenterology</i> , 2012, 18, 6475.	1.4	33

#	ARTICLE	IF	CITATIONS
91	Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. <i>Complementary Therapies in Medicine</i> , 2014, 22, 17-20.	1.3	32
92	Increased Long-term Dietary Fiber Intake Is Associated With a Decreased Risk of Fecal Incontinence in Older Women. <i>Gastroenterology</i> , 2018, 155, 661-667.e1.	0.6	30
93	Factor analysis of bowel symptoms in US and Italian populations. <i>Digestive and Liver Disease</i> , 2003, 35, 774-783.	0.4	29
94	Rome foundation Asian working team report: Real world treatment experience of Asian patients with functional bowel disorders. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1450-1456.	1.4	29
95	Rome IV Functional Gastrointestinal Disorders and Health Impairment in Subjects With Hypermobility Spectrum Disorders or Hypermobility Ehlers-Danlos Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 277-287.e3.	2.4	29
96	If We Don't Ask, They Won't Tell: Screening for Urinary and Fecal Incontinence by Primary Care Providers. <i>Journal of the American Board of Family Medicine</i> , 2018, 31, 774-782.	0.8	28
97	Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and non-GI symptoms and report differences in healthcare utilization: A population-based study. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13483.	1.6	28
98	Conservative and behavioural management of constipation. <i>Neurogastroenterology and Motility</i> , 2009, 21, 55-61.	1.6	25
99	Factors That Affect Consultation and Screening for Fecal Incontinence. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 709-716.	2.4	25
100	Menopausal Hormone Therapy Is Associated With Increased Risk of Fecal Incontinence in Women After Menopause. <i>Gastroenterology</i> , 2017, 152, 1915-1921.e1.	0.6	24
101	Definition of a responder in clinical trials for functional gastrointestinal disorders: report on a symposium. <i>Gut</i> , 1999, 45, ii78-ii79.	6.1	23
102	Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination. <i>American Journal of Medicine</i> , 1999, 107, 33-40.	0.6	23
103	Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12919.	1.6	23
104	Relationship between symptoms and quality of life in fecal incontinence. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13241.	1.6	22
105	Validity and reliability of the Malay language translation of the Rome III Diagnostic Questionnaire for irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 746-750.	1.4	20
106	Physical Activity, BMI, and Risk of Fecal Incontinence in the Nurses' Health Study. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e200.	1.3	20
107	Priorities for treatment research from different professional perspectives. <i>Gastroenterology</i> , 2004, 126, S180-S185.	0.6	19
108	Treating Fecal Incontinence: An Unmet Need in Primary Care Medicine. <i>North Carolina Medical Journal</i> , 2016, 77, 211-215.	0.1	19

#	ARTICLE	IF	CITATIONS
109	Improving biofeedback for the treatment of fecal incontinence in women: implementation of a standardized multi-site manometric biofeedback protocol. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12906.	1.6	19
110	Functional gastrointestinal disorders are increased in joint hypermobility-related disorders with concomitant postural orthostatic tachycardia syndrome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13975.	1.6	19
111	Phenotypic profile clustering pragmatically identifies diagnostically and mechanistically informative subgroups of chronic pain patients. <i>Pain</i> , 2021, 162, 1528-1538.	2.0	19
112	Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. <i>United European Gastroenterology Journal</i> , 2021, 9, 1178-1188.	1.6	18
113	Controlling anal incontinence in women by performing anal exercises with biofeedback or loperamide (CAPABLE) trial: Design and methods. <i>Contemporary Clinical Trials</i> , 2015, 44, 164-174.	0.8	17
114	Biomarkers to distinguish functional constipation from irritable bowel syndrome with constipation. <i>Neurogastroenterology and Motility</i> , 2016, 28, 783-792.	1.6	17
115	A genetic polymorphism that is associated with mitochondrial energy metabolism increases risk of fibromyalgia. <i>Pain</i> , 2020, 161, 2860-2871.	2.0	17
116	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14070.	1.6	17
117	Development and validation of new disease-specific measures of somatization and comorbidity in IBS. <i>Journal of Psychosomatic Research</i> , 2012, 73, 351-355.	1.2	16
118	Factors associated with fecal incontinence in a nationally representative sample of diabetic women. <i>International Urogynecology Journal</i> , 2015, 26, 1483-1488.	0.7	16
119	Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 14-26.	1.9	16
120	Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13378.	1.6	16
121	Hypnosis for non-cardiac chest pain. <i>Gut</i> , 2006, 55, 1381-1384.	6.1	15
122	A multicenter study of anorectal pressures and rectal sensation measured with portable manometry in healthy women and men. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14067.	1.6	14
123	Patient preferences for endpoints in fecal incontinence treatment studies. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13032.	1.6	11
124	Disorders of gut-brain interaction: Highly prevalent and burdensome yet under-taught within medical education. <i>United European Gastroenterology Journal</i> , 2022, 10, 736-744.	1.6	10
125	Obstetric Sphincter Injury Interacts With Diarrhea and Urgency to Increase the Risk of Fecal Incontinence in Women With Irritable Bowel Syndrome. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2013, 19, 40-45.	0.6	9
126	Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1315-1325.e4.	2.4	9

#	ARTICLE	IF	CITATIONS
127	Likelihood of Nursing Home Referral for Fecally Incontinent Elderly Patients is Influenced by Physician Views on Nursing Home Care and Outpatient Management of Fecal Incontinence. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 350-354.	1.2	8
128	Impact of Eating Restriction on Gastrointestinal Motility in Adolescents With IBS. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2014, 58, 491-494.	0.9	7
129	Is Fecal Incontinence a Risk Factor for Institutionalization in the Elderly?. <i>American Journal of Gastroenterology</i> , 2011, 106, 366-367.	0.2	6
130	Biofeedback for fecal incontinence and constipation: The role of medical management and education. <i>Gastroenterology</i> , 2001, 120, A397.	0.6	5
131	Hypnosis and upper digestive function and disease. <i>World Journal of Gastroenterology</i> , 2008, 14, 6276.	1.4	5
132	Comparative effectiveness of biofeedback and injectable bulking agents for treatment of fecal incontinence: Design and methods. <i>Contemporary Clinical Trials</i> , 2021, 107, 106464.	0.8	4
133	Adopting new enrollment criteria for pharmaceutical trials in constipation: look before leaping. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 165-168.	1.4	2
134	Validity and Reliability of the Malay Versions of Bloating Severity (BSQ-M) and Quality of Life (BLQoL-M) Questionnaires. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2487.	1.2	2
135	Proinflammatory Diet Is Associated With Increased Risk of Fecal Incontinence Among Older Women: Prospective Results From the Nurses' Health Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1657-1659.e3.	2.4	2
136	Anorectal physiology in health: A randomized trial to determine the optimum catheter for the balloon expulsion test. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13582.	1.6	1
137	Constipation. <i>Obstetrics and Gynecology</i> , 2007, 109, 985-989.	1.2	0
138	Is biofeedback therapy an effective treatment for dyssynergic defecation?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 74-75.	1.7	0
139	Editorial: <sc>ONO</sc>â€2952 in irritable bowel syndrome with diarrhoea â€“ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1005-1005.	1.9	0
140	The Prevalence and Risk of Fecal Incontinence in Patients with Cystic Fibrosis: Nothing to Sneeze At. <i>Digestive Diseases and Sciences</i> , 2018, 63, 818-819.	1.1	0
141	Fecal Incontinence. , 2020, , 427-430.		0